Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Fish Oils in Lupus
ISRCTN ISRCTN66445141
ClinicalTrials.gov identifier
Public title Fish Oils in Lupus
Scientific title Omega-3-polyunsaturated fatty acids and atherosclerosis in systemic lupus erythematosus: cellular mechanisms and functional consequences
Acronym N/A
Serial number at source 073400
Study hypothesis AIMS:
1. To examine platelet free radical (nitric oxide and superoxide) generation in Systemic Lupus Erythematosus (SLE)
2. To examine endothelial function and vascular reactivity in systemic lupus erythematosus at global, local and microvascular levels
3. To examine the effect of omega-3 polyunsaturated fatty acids in relation to markers of platelet activation, vascular reactivity and disease activity in systemic lupus erythematosus
Lay summary
Ethics approval QUB Research Ethics Committee (reconstituted to ORECNI 2004) gave approval on the 28th May 2003 (MHRA letter of approval on 10th December 2004). Reference numbers:
1. Ethics: 158/03
2. Trust: 04/SW/114
3. Eudract No.: 2004-004404-21
4. CTA No.: 21993-0002-001-0001
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Systemic Lupus Erythematosus (SLE)
Participants - inclusion criteria Patients (adult, either sex) fulfilling American College of Rheumatology (ACR) classification criteria for SLE.
Participants - exclusion criteria 1. Diabetes mellitus (fasting blood glucose more than 7.8 mmol/l)
2. Hypertension of systolic more than 160 mmHg or diastolic more than 90 mmHg (as determined by the mean of three readings taken on the first visit)
3. Carcinoma (other than superficial skin carcinoma)
4. Significant pulmonary, hepatic or renal disease
5. Typical angina or myocardial infarction
6. Active infectious diseases
7. Use of antihypertensive, oral hypoglycaemic or lipid lowering agent (in the last three months)
8. Cyclophosphamide therapy (due to potential to interfere with acetylcholinesterase)
9. Glucocorticoids equivalent to greater than 10 mg prednisolone
10. All pregnant or lactating women will be excluded.
Anticipated start date 01/01/2005
Anticipated end date 01/08/2006
Status of trial Completed
Patient information material
Target number of participants 60
Interventions SLE subjects will be randomised to either fish oil capsules or placebo for a 24 week period. The patients will have measures of endothelial function and vascular reactivity, free radical activity and markers of disease activity taken at baseline, 12 weeks and at 24 weeks.

Joint sponsor details:
Greenpark Healthcare Trust
Research Department
Musgrave Park Hospital
Stockmans Lane
Belfast
BT9 7JB
Northern Ireland
Tel: +44 (0)28 9090 2000
Fax: +44 (0)28 9066 1112
email: ruth.alexander@greenpark.n-I.nhs.uk
Primary outcome measure(s) Improved nitric oxide bioactivity and reduced superoxide bioactivity.
Secondary outcome measure(s) Improved vascular reactivity and endothelial function, clinical response as measured by Revised activity index of Systemic Lupus Activity Measure (SLAM-R), Systemic Lupus International Collaborating Clinics (SLICC) and British Isles Lupus Assessment Group (BILAG).
Sources of funding The Wellcome Trust (UK) (grant ref: 073400)
Trial website
Publications 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/17875549
Contact name Dr  Gary  McVeigh
  Address Queen's University of Belfast
Whitla Medical Building
Department of Therapeutics and Pharmacology
97 Lisburn Road
  City/town Belfast
  Zip/Postcode BT7 1BL
  Country United Kingdom
  Tel +44 (0)28 9097 5770
  Fax +44 (0)28 9043 8346
  Email g.mcveigh@qub.ac.uk
Sponsor Queen's University of Belfast (UK)
  Address Lanyon North
Regional Research Services
University Road
  City/town Belfast
  Zip/Postcode BT7 1NN
  Country United Kingdom
  Tel +44 (0)28 9097 2568
  Fax +44 (0)28 9097 2570
  Email d.weir@qub.ac.uk
  Sponsor website: http://www.qub.ac.uk/
Date applied 22/07/2005
Last edited 26/01/2009
Date ISRCTN assigned 22/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central